A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
Clinical trial NCT07441512 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07441512
- Sponsor
- Hu Hai
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-15
- Primary completion
- 2028-03-15
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.